Celltrion, Inc.
KSC: 068270.KS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Korea Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Woo-Sung Kee
- Employees
- 2,391
- Headquarters
- Incheon, South Korea
- IPO year
- 2005
- Market cap
- ₩43.4T
- Website
- https://www.celltrion.com
Loading 068270…
Loading profile data…Frequently asked questions about 068270
What does Celltrion, Inc. (068270.KS) do?
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticari...
Where does 068270.KS trade?
Celltrion, Inc. (068270.KS) trades on the Korea Exchange.
What sector is 068270.KS in?
Celltrion, Inc. (068270.KS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Celltrion, Inc.?
Woo-Sung Kee is the chief executive officer of Celltrion, Inc. (068270.KS).
Where is Celltrion, Inc. headquartered?
Celltrion, Inc. is headquartered in South Korea.
Does 068270.KS pay a dividend?
Yes — Celltrion, Inc. (068270.KS) paid a trailing twelve-month dividend of KRW 750.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 068270.KS go public?
Celltrion, Inc. (068270.KS) completed its initial public offering in 2005.